Nibix (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. By stopping the phosphorylation cascade, the drug halts uncontrolled cell division and triggers programmed cell death in malignant cells that depend on these pathways.

The dose of Nibix is individualized by the prescribing physician based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and response to therapy. No standard dose is provided here; the prescriber determines the appropriate regimen.

Safety data for imatinib in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To order Nibix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nibix (imatinib) is the first‑generation BCR‑ABL inhibitor and is generally well‑tolerated. Newer agents such as dasatinib or nilotinib may offer activity against some imatinib‑resistant mutations but can have different safety profiles, including higher rates of vascular events. Choice of therapy depends on mutation status, prior treatment and patient comorbidities.

Store Nibix at room temperature, below 25 °C, in the original container. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Nibix is taken orally, usually with a glass of water. It can be swallowed with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the prescriber’s instructions regarding timing and any required dose adjustments.

The most critical adverse events include severe neutropenia or thrombocytopenia, which can lead to infection or bleeding, hepatotoxicity with possible liver failure, cardiac dysfunction such as congestive heart failure, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome.

Nibix is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe liver impairment, uncontrolled cardiac disease, or those receiving interacting medications that cannot be safely managed.